Can-Fite BioPharma (NYSE:CANF) Downgraded to Sell Rating by StockNews.com

Can-Fite BioPharma (NYSE:CANF) was downgraded by equities research analysts at StockNews.com from a “hold” rating to a “sell” rating in a report released on Wednesday.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $18.00 target price on shares of Can-Fite BioPharma in a research report on Tuesday, November 12th.

Can-Fite BioPharma Stock Down 2.0 %

NYSE CANF opened at $1.97 on Wednesday. The company has a market cap of $6.97 million, a price-to-earnings ratio of -1.13 and a beta of 1.39. Can-Fite BioPharma has a 52 week low of $1.87 and a 52 week high of $4.69. The business has a 50 day moving average price of $2.23 and a 200-day moving average price of $2.52.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Can-Fite BioPharma stock. Armistice Capital LLC raised its position in Can-Fite BioPharma Ltd. (NYSE:CANF) by 35.5% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 518,853 shares of the company’s stock after buying an additional 136,055 shares during the quarter. Armistice Capital LLC owned about 14.66% of Can-Fite BioPharma worth $1,339,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 21.00% of the company’s stock.

About Can-Fite BioPharma

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.